While a large number of mosquito-transmitted alphaviruses are known to cause serious human 21 diseases, there are no licensed vaccines that protect against alphavirus infections. The alphavirus 22 chikungunya virus (CHIKV) has caused multiple recent outbreaks of chikungunya fever. This 23 virus has the potential to cause a worldwide epidemic and has generated strong interest in 24 development of a prophylactic CHIKV vaccine. We report here on the development of a potent 25 experimental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) 26 expressing the entire CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV 27 glycoprotein (G). These VSVΔG-CHIKV chimeras incorporated functional CHIKV 28 glycoproteins into the viral envelope in place of VSV G. The chimeric viruses were attenuated 29 for growth in tissue culture, but could be propagated to high titers without VSV G 30 complementation. They also generated robust neutralizing antibody and cellular immune 31 responses to CHIKV in mice after a single dose, and protected mice against CHIKV infection. 32 VSV∆G-alphavirus chimeras could have general applicability as alphavirus vaccines.
In this study, we initially wanted to determine if we could construct VSV-based vaccine 76 vectors expressing the entire CHIKV E3-E2-6K-E1 precursor polyprotein. We did this in a full-77 length VSV construct as well as in a VSVΔG construct (lacking the VSV glycoprotein gene). Lysates were collected and clarified at 16,000 x g for 2 min at 4°C. To label rVSVs, BHK-21 139 cells on 6 cm dishes were infected with rwt-VSV, VSV-CHIKV or VSVΔG-CHIKV at an MOI 140 of 100. After adsorption for 1 h, virus was removed and replaced with DMEM containing 5% 141 FBS. After 2 h, cells were washed two-times with pre-warmed methionine-free DMEM. 142
Subsequently, labeling media (90% methionine-free DMEM + 9% serum-free DMEM + 1% 143 FBS) containing 300 μCi of [
35 S]-methionine was added to each dish and incubated over night at 144 37°C. Virus supernatants were collected after 20 h, clarified at 16,000 x g for 5 min to remove 145 cell debris, layered onto a 20% sucrose gradient (in 10 mM Tris pH 7.4) and centrifuged for 1 h 146 at 38,000 rpm at 4°C. Virus pellet was dissolved in TE. 147
Labeled viruses and cell lysates were analyzed on a 4-12% Bis-Tris NuPAGE gel 148 (Invitrogen, CA) and protein bands were imaged using a Fujifilm BAS 1800 imaging system. were inoculated with recombinant VSV vectors using 10 6 plaque forming units (PFU) per mouse 162 by the intramuscular (I.M.) route in a volume of 50 μl of serum-free DMEM administered into 163 the right hind leg muscle. For the challenge study, 3 week old female C57Bl/6 mice were 164 obtained from Jackson Laboratories, ME and acclimatized for 4 days before immunization. 165
Blood was collected at 30 days post immunization (dpi) from retro-orbital sinus. These animals 166
were challenged with the wild-type CHIKV-LR strain derived from a cDNA clone (39) using 10 4 167 PFU per mouse by the subcutaneous (S.C.) route in the left rear footpad. Foot swelling 168 measurements were taken on the day of challenge and for 10 days following using a caliper to 169 measure the height of the foot at the ball. Animals from each immunization group were divided 170 into two subgroups and were bled on alternate days post challenge to measure viral titers by 171 plaque assay on Vero cells. Two animals from each group were sacrificed at 4 days post 172 challenge (38 dpi) for histopathology analysis. UV inactivation of virus was performed using 173 two exposures of virus to 5 x 10 5 μJoules in a UV Stratalinker 1800 (Stratagene). 174
9
To look at cellular immune responses, 6-8-week-old female C57Bl/6 mice wereinoculated with virus after 1-week acclimatization, and sacrificed by anesthesia overdose at 7 dpi 176 for isolating splenocytes. Immunization and challenge study. Fig. 4A shows the timeline of the 280 immunization/challenge study using 3.5 week-old C57Bl/6 mice. Two groups of eight mice each 281 were immunized I.M. with VSV-CHIKV or VSVΔG-CHIKV and a control group (n=8) received 282 rwt-VSV. Blood was collected from the animals at day 30-post immunization and used to 283 determine the CHIKV nAb response from each group. As shown in Fig. 4B , while both 284 VSV/CHIKV recombinants elicited 100% neutralization of VSV/CHIKV pseudotypes 285 (homologous S27 strain) at low dilution, VSVΔG-CHIKV induced a superior response at 286 dilutions greater than 1:160. However, the differences between the two vaccine groups did not 287 reach statistical significance. Control rwt-VSV immunized mice had no CHIKV nAb. To assess 288
on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from neutralization tests (PRNT) were also performed using these serum samples. As shown in Table  290 1, all rVSV/CHIKV immunized animals had PRNT 80 titers of ≥80 with the VSVΔG-CHIKV 291
group showing a higher nAb titer on average (ranging from 160 to >640) compared to VSV-292 CHIKV group (titer ranging from 80 to 320). Control mice that received rwt-VSV showed titers 293 below the detection limit (<20). Anti-vector nAb titers directed against VSV G were also 294 measured using pooled serum samples from each immunization group (not shown). disease, the immunized C57Bl/6 mice were subjected to S.C. challenge in their rear left footpad 300 with 10 4 PFU of CHIKV-LR strain at 34 days post immunization and followed for signs of 301 disease over 10 subsequent days. Four mice from each immunization group were bled on 302 alternate days post challenge to assess viremia. Control animals that received rwt-VSV showed 303 viremia during the first two days after challenge while none of the rVSV/CHIKV-vaccinated 304 mice had detectible viremia (Table 2) . CHIKV induced disease was also monitored for 10 days 305 post challenge by following signs of local inflammation as measured by swelling of the 306 inoculated foot. As shown in Fig. 5A , rwt-VSV immunized control animals displayed 307 substantial footpad swelling that was sustained for 10 days after challenge. In contrast, mice in 308 both the rVSV/CHIKV-vaccinated groups separately showed significantly less (p<0.001, 309 ANOVA) foot swelling, which returned to pre-challenge levels by day 8 or 9 post challenge (Fig.  310   5A ). While the control animals showed a transient weight loss or failed to gain weight after 311 on October 20, 2017 by guest http://jvi.asm.org/ Downloaded from 5B). However, the differences in weight loss did not reach statistical significance because of the 313 high degree of animal-to-animal variability. 314
Two animals from each group were sacrificed at day 4-post challenge for histopathologic 315 evaluation (not shown). The brain, lung, heart, kidney, bowel, spleen, and muscle, demonstrated 316 no significant histopatholgic differences among the groups. It is possible that we might have 317 noted more significant histopathologic change at later times after infection. This has been noted 318 by others in the muscle at day 7 following challenge (8). We did however note microgranulomas 319 in the liver of all groups, and the vaccine groups showed a 75% reduction in the number of 320 microgranulomas compared to the rwt-VSV control group. These microgranulomas most likely 321 represent a non-specific reaction to hepatic injury. 322 VSV/CHIKV recombinants induce cellular immune responses in C57Bl/6 mice. 323
Because VSV based vaccine vectors are known to be potent inducers of both humoral and 324 cellular immune responses (28, 47), we also looked at the CHIKV specific cellular immune 325 response to the VSV/CHIKV vectors. A previous study, using a multi-dose DNA vaccine 326 expressing consensus CHIKV E1 or E2 sequences, reported induction of CHIKV specific CD8 + 327 CTL responses using peptide pools, and predicted two dominant CD8 + epitopes one in E1 328 protein and one in E2 protein (19). We used synthetic peptides corresponding to these predicted 329 epitopes (HSMTNAVTI on E1 and IILYYYELY on E2) in an IFN-γ ELISPOT assay. Our 330 studies (Fig. 6) 
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